Jun 22, 2021 / 03:20PM GMT
Tony Cataldo - GT Biopharma, Inc. - Chairman, CEO & President
All right. Hi, it's Tony Cataldo. For those of you out there, I'm the Chairman and CEO of GT Biopharma, Inc. We're a Nasdaq-traded company, and we uplisted on February 15. And most recent events that are relevant is that we had some tremendous progress. We've been pretty lucky at that. But what I always like to do is start these meetings -- there is a forward-looking statement, which is basically we're not supposed to lie to you, okay?
The good thing about biotech is -- what I always say to folks is I think CEOs talk way too much. And I think really, it's not us that you should listen to at a biotech company. The voice of the company has to be the data: clinical trial data, human FDA clinical trial data. And that's what we're going to focus on today. We're going to tell you about what the TriKE is, we're going to get into the clinical trial data. And then we're going to leave the floor open for those of you who have any questions so that we can address what you came here -- and make sure you get out of this what you sought.
GT Biopharma Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers